MDCX

Medicus Pharma Ltd. stock has experienced volatility driven by clinical trial results and regulatory news, with a decline of approximately 86.04% over the last six months and 92.33% over the past year. In May 2026, Medicus Pharma announced positive dose-response results from a pre-specified expanded Phase 2 SKNJCT-003 data analysis. In April 2026, the CEO met with lawmakers, submitted an Orphan Drug Designation Application for SkinJect in Gorlin Syndrome, presented new Teverelix data, and submitted an optimized Phase 2 study protocol for Teverelix in acute urinary retention. In March 2026, the company reported full-year 2025 financial results and highlighted the completed 90-patient Phase 2 SkinJect study, but the stock plummeted due to skepticism around regulatory pathways and financial sustainability. In December 2025, Carolyn Bonner was appointed as CFO. Medicus Pharma received a Nasdaq non-compliance notice and is pursuing a share consolidation to regain compliance.